BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gomez DR, Rimner A, Simone CB 2nd, Cho BCJ, de Perrot M, Adjei AA, Bueno R, Gill RR, Harpole DH Jr, Hesdorffer M, Hirsch FR, Jackson AA, Pass HI, Rice DC, Rusch VW, Tsao AS, Yorke E, Rosenzweig K. The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2019;14:1172-1183. [PMID: 31125736 DOI: 10.1016/j.jtho.2019.03.030] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Hanna GG, John T, Ball DL. Controversies in the role of radiotherapy in pleural mesothelioma. Transl Lung Cancer Res 2021;10:2079-87. [PMID: 34012816 DOI: 10.21037/tlcr-20-583] [Reference Citation Analysis]
2 Lazarev S, Rosenzweig K, Samstein R, Salgado LR, Hasan S, Press RH, Sharma S, Powell CA, Hirsch FR, Simone CB 2nd. Where are we with proton beam therapy for thoracic malignancies? Current status and future perspectives. Lung Cancer 2021;152:157-64. [PMID: 33421922 DOI: 10.1016/j.lungcan.2020.12.025] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Zeng J, Badiyan SN, Garces YI, Wong T, Zhang X, Simone CB 2nd, Chang JY, Knopf AC, Mori S, Iwata H, Meijers A, Li H, Bues M, Liu W, Schild SE, Rengan R;  International Particle Therapy Cooperative Group Thoracic Subcommittee. Consensus Statement on Proton Therapy in Mesothelioma. Pract Radiat Oncol. 2021;11:119-133. [PMID: 32461036 DOI: 10.1016/j.prro.2020.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cui W, Popat S. Pleural mesothelioma (PM) - The status of systemic therapy. Cancer Treat Rev 2021;100:102265. [PMID: 34399145 DOI: 10.1016/j.ctrv.2021.102265] [Reference Citation Analysis]
5 Ke H, Kao S, Lee K, Takahashi K, Goh HP, Linton A. The minimum standard of care for managing malignant pleural mesothelioma in developing nations within the Asia-Pacific Region. Asia Pac J Clin Oncol 2021. [PMID: 34161674 DOI: 10.1111/ajco.13611] [Reference Citation Analysis]
6 Nowak AK, Jackson A, Sidhu C. Management of Advanced Pleural Mesothelioma-At the Crossroads. JCO Oncol Pract 2021;:OP2100426. [PMID: 34491782 DOI: 10.1200/OP.21.00426] [Reference Citation Analysis]
7 Barsky AR, Ahern CA, Venigalla S, Verma V, Anstadt EJ, Wright CM, Ludmir EB, Berlind CG, Lindsay WD, Grover S, Cengel KA, Simone CB 2nd. Gender-based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma. Clin Lung Cancer 2020;21:e583-91. [PMID: 32611504 DOI: 10.1016/j.cllc.2020.05.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Wadowski B, De Rienzo A, Bueno R. The Molecular Basis of Malignant Pleural Mesothelioma. Thorac Surg Clin 2020;30:383-93. [PMID: 33012428 DOI: 10.1016/j.thorsurg.2020.08.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Davis AP, Kao SC, Clarke SJ, Boyer M, Pavlakis N. Emerging biological therapies for the treatment of malignant pleural mesothelioma. Expert Opin Emerg Drugs 2021;26:179-92. [PMID: 33945357 DOI: 10.1080/14728214.2021.1924670] [Reference Citation Analysis]
10 Trovo M, Relevant A, Polesel J, Muraro E, Barresi L, Drigo A, Baresic T, Bearz A, Fanetti G, Del Conte A, Matrone F, Reverberi C, Furlan C, Zuccon U, Fontana P, Franchin G, Minatel E. Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2021;109:1368-1376. [PMID: 33259933 DOI: 10.1016/j.ijrobp.2020.11.057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Patel R, Ludmir EB, Miccio JA, Menon H, Barsky AR, Mesko SM, Kodali M, Lautenschlaeger T, Adeberg S, Simone CB 2nd, Verma V. Disease-Related Outcomes and Toxicities of Intensity Modulated Radiation Therapy After Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review. Pract Radiat Oncol. 2020;10:423-433. [PMID: 32088429 DOI: 10.1016/j.prro.2020.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Hung YP, Chirieac LR. Pathology of Malignant Pleural Mesothelioma. Thorac Surg Clin 2020;30:367-82. [PMID: 33012427 DOI: 10.1016/j.thorsurg.2020.08.007] [Reference Citation Analysis]
13 Müdder T, Sarria GR, Henkenberens C, Holz J, Garbe S, Röhner F, Stumpf S, Buchstab T, Giordano FA, Leitzen C. Dosimetric Comparison Between Helical Tomotherapy and Volumetric Modulated Arc Therapy in Patients With Malignant Pleural Mesothelioma. Clin Oncol (R Coll Radiol) 2021:S0936-6555(21)00291-0. [PMID: 34429236 DOI: 10.1016/j.clon.2021.08.005] [Reference Citation Analysis]
14 Luna J, Bobo A, Cabrera-Rodriguez JJ, Pagola M, Martín-Martín M, Ruiz MÁG, Montijano M, Rodríguez A, Pelari-Mici L, Corbacho A, Moreno M, Couñago F. GOECP/SEOR clinical guidelines on radiotherapy for malignant pleural mesothelioma. World J Clin Oncol 2021; 12(8): 581-608 [PMID: 34513595 DOI: 10.5306/wjco.v12.i8.581] [Reference Citation Analysis]
15 Pasalic D, Betancourt-Cuellar SL, Taku N, Ludmir EB, Lu Y, Allen PK, Tang C, Antonoff MB, Fuller CD, Rosenthal DI, Morrison WH, Phan J, Garden AS, Welsh JW, Chang JY, Liao Z, Erasmus JJ, Nguyen QN. Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head Neck 2020;42:1939-53. [PMID: 32129548 DOI: 10.1002/hed.26117] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
16 Rosenzweig KE. Radiation Therapy for Malignant Pleural Mesothelioma. Thorac Surg Clin 2020;30:473-80. [PMID: 33012434 DOI: 10.1016/j.thorsurg.2020.08.006] [Reference Citation Analysis]
17 Gray SG. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma. BMC Pulm Med 2021;21:148. [PMID: 33952230 DOI: 10.1186/s12890-021-01513-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Gray SG, Mutti L. Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. Transl Lung Cancer Res 2020;9:S100-19. [PMID: 32206576 DOI: 10.21037/tlcr.2019.11.23] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
19 Ghirardelli P, Franceschini D, D'Aveni A, Dominici L, Ravasio A, Marzo M, Villa E, Di Noia V, Scorsetti M, Vavassori V, Ceresoli GL. Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma. Lung Cancer 2021;152:1-6. [PMID: 33310300 DOI: 10.1016/j.lungcan.2020.11.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]